Furmonertinib mesylate is under clinical development by Arrivent Biopharma and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Furmonertinib mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Furmonertinib mesylate overview

Alflutinib mesylate (Ivesa, Furmonertinib Mesilate) acts as an anti-cancer agent. It is formulated as tablets for oral route of administration. Ivesa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with positive EGFR T790M mutation.

Alflutinib mesylate (AST-2818) is under development for the treatment of lung adenocarcinoma and non-small cell lung cancer (NSCLC). The drug candidate is administered through the oral route. It is a third-generation T790M drug-resistant candidate which acts by targeting epidermal growth factor receptor (EGFR) mutation selective tyrosine kinase.

Arrivent Biopharma overview

Arrivent Biopharma (Arrivent) is engaged in discovery and development of medicines for treatment of cancer. The company is developing its lead product candidate Furmonertinib, an oral pan-EGFR mutant inhibitor for treatment of non-small cell lung cancer (NSCLC). It is also evaluating ARR-002 program to treat solid tumors. Arrivent works in collaboration with Allist and Aarvik therapeutics. The company was funded by Octagon capital advisors, lilly Asia ventures, Orbimed healthcare fund management, and Zoo cap. Arrivent is headquartered in Newtown Square, Pennsylvania, the US.

For a complete picture of Furmonertinib mesylate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.